Current State of Cardiorenal Disease in People with Type 1 Diabetes [0.03%]
1 型糖尿病患者的 cardiorenal 疾病的现状
Stuti Fernandes,Barbara Hettinger,Lynn Ang et al.
Stuti Fernandes et al.
This article highlights the increased risk of cardiovascular and renal disease in individuals with type 1 diabetes (T1D). In recent years, the treatment landscape of type 2 diabetes has been revolutionized beyond strictly glycemic and metab...
GLP-1 Receptor Agonists May Reduce Insulin Requirements in New-Onset Type 1 Diabetes [0.03%]
GLP-1受体激动剂可能减少新发1型糖尿病的胰岛素需求量
Justin M Gregory
Justin M Gregory
Early stage 3 type 1 diabetes is a period of rapid pathophysiologic change. Flagging beta-cell secretion is accompanied by postprandial hyperglucagonemia, impaired incretin amplification, beta-cell stress, and insulin resistance. Incretin-b...
Weekly Glucagon-Like Peptide-1 Receptor Agonists in Type 1 Diabetes: What We Know So Far and Future Trials [0.03%]
周制剂胰高血糖素样肽-1受体激动剂在1型糖尿病中的研究进展及未来试验方向
Amy Stein,Meghan Pauley,Janet Snell-Bergeon
Amy Stein
Type 1 diabetes (T1D) results in lifelong insulin therapy, but most people with T1D do not achieve glycemic targets using insulin alone. Adjunctive therapies such as once-weekly glucagon-like peptide-1 receptor agonists (GLP-1 RA) are appro...
Daily Glucagon-like Peptide-1 Receptor Agonists in Type 1 Diabetes: What we've Learned and What Comes Next [0.03%]
每日一次的GLP-1受体激动剂用于治疗1型糖尿病：我们的经验与未来展望
Rachael Innes,John R Petrie,Thomas Fremming Dejgaard
Rachael Innes
Phase 2 clinical trials using daily injectable glucagon-like peptide-1 receptor agonists as adjunct therapy in type 1 diabetes showed promising signals for efficacy on glycemic control and weight. These effects were confirmed in larger phas...
Beyond Glycemia in T1D: Insulin Resistance and Multiorgan Injury in Type 1 Diabetes-Part 2 [0.03%]
1型糖尿病中的血糖以外的问题：第2部分：1型糖尿病中的胰岛素抵抗和多器官损伤
Jairo A Pinzon Cortes,Phoom Narongkiatikhun,Coco Fuhri Snethlage et al.
Jairo A Pinzon Cortes et al.
Insulin resistance (IR) in type 1 diabetes drives multiorgan injury that extends far beyond glycemic dysregulation. Subcutaneous insulin delivery reverses the portal-to-peripheral insulin gradient, downregulating peripheral insulin receptor...
Beyond Glycemia in T1D: The Hidden Burden of Insulin Resistance and Cardiorenal Risk in Type 1 Diabetes-Part 1 [0.03%]
1型糖尿病的隐性负担：胰岛素抵抗和心肾风险——第1部分
Jairo A Pinzon Cortes,Phoom Narongkiatikhun,Coco M Fuhri Snethlage et al.
Jairo A Pinzon Cortes et al.
Insulin resistance (IR) is an underrecognized feature of type 1 diabetes (T1D), present even in lean individuals. Rising obesity rates have further amplified this burden, creating a mixed metabolic phenotype that accelerates cardiorenal dis...
Huajing Ni,Jennifer R Snaith,Jerry R Greenfield
Huajing Ni
A century after the discovery of insulin, people with type 1 diabetes continue to experience elevated cardiovascular risk and associated mortality, incompletely explained by dysglycemia and traditional risk factors. There is increasing reco...
Navigating Adrenal Disease: A Comprehensive, Practical Guide for the Clinician [0.03%]
肾上腺疾病诊治指南：临床医生的实用参考书
Smita B Abraham
Smita B Abraham
Justin Mathew,Alyssa Yeung
Justin Mathew
Adrenal disorders in pregnancy are rare but often clinically significant. Diagnosis is challenging owing to overlap with normal physiologic changes in pregnancy. Early diagnosis is often key, ideally before pregnancy. Cushing's syndrome and...
Vania Balderrama-Brondani,Mouhammed Amir Habra
Vania Balderrama-Brondani
Adrenocortical carcinoma (ACC) is a rare, aggressive malignancy with symptoms arising from mass effect or hormonal excess, particularly hypercortisolism. Accurate diagnosis requires comprehensive clinical, hormonal, radiologic, and histopat...